Real-life first dose effect of Fasenra in patients with Severe Uncontrolled Asthma

Trial Identifier:	D3250R00061
Sponsor:	AstraZeneca
NCTID::	NCT04200326
Start Date:	December 2019
Primary Completion Date:	April 2020
Study Completion Date:	April 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version
	English GB Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United Kingdom	London, United Kingdom, SE1 9RT

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.